Addison Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Addison Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$277	Hold	5	–	–	﹤0.01%	762
2026 Q2	$273	Hold	5	–	–	﹤0.01%	672
2026 Q1	$238	Hold	5	–	–	﹤0.01%	956
2025 Q4	$263	Hold	5	–	–	﹤0.01%	877
2025 Q3	$325	Hold	5	–	–	﹤0.01%	862
2025 Q2	$244	Hold	5	–	–	﹤0.01%	857
2025 Q1	$171	Hold	5	–	–	﹤0.01%	820
2024 Q4	$197	Hold	5	–	–	﹤0.01%	822
2024 Q3	$235	Hold	5	–	–	﹤0.01%	816
2024 Q2	$271	Hold	5	–	–	﹤0.01%	754
2024 Q1	$341	Hold	5	–	–	﹤0.01%	676
2023 Q4	$313	Hold	5	–	–	﹤0.01%	684
2023 Q3	$227	Buy	+5	New	+$258	﹤0.01%	657

Other funds holding CRSP

GSK plc London $497M AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Addison Advisors's CRSP Position: Q3 2026 in Review

Addison Advisors held its CRISPR Therapeutics (CRSP) position steady in Q3 2026 at 5 shares worth $277. The position accounts for ﹤0.01% of the portfolio, ranked #762.

Addison Advisors first reported a position in CRSP in Q3 2023 and has held it in 13 quarters since. The position peaked at $341 in Q1 2024. 256 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

Addison Advisors held 5 shares of CRISPR Therapeutics worth $277 as of Q3 2026.
Addison Advisors left its CRISPR Therapeutics share count unchanged in Q3 2026.
CRISPR Therapeutics made up ﹤0.01% of Addison Advisors's portfolio in Q3 2026, its #762 holding.
Addison Advisors first reported a position in CRISPR Therapeutics in Q3 2023 and has held it in 13 quarters since.
Addison Advisors's CRISPR Therapeutics position peaked at $341 in Q1 2024.
256 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Addison Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.